STORY FROM: Drugs & Medical Devices
Journal Top Ten
September 1, 2002
photo-7 Related Drug: Avandia
Article: "Severe Cholestatic Hepatitis Caused by Thiazolidinediones: Risks Associated with Substituting Rosiglitazone for Troglitazone"
Summary: The association between troglitazone and severe hepatotoxicity led to the drug's removal from the U.S. market in 2000. Rosiglitazone is currently marketed as a safer alternative for the treatment of type 2 diabetes mellitus. This is a case report of a 56-year old woman who was diagnosed with thiazolidinedione-induced cholestatic hepatitis after ingesting 8 mg/day of rosiglitazone. She had previously developed mild hepatotoxicity while taking troglitazone. Liver function tests performed after the switch showed moderate increases in serum alkaline ...